Key Takeaways
- The U.S. FDA has upgraded the recall of 30mg Thyroid Tablets to a Class I designation.
- The tablets, manufactured by Vitruvias Therapeutics, are described as superpotent, posing severe health risks.
- The recall covers around 1,955 units distributed nationwide between January and September 2025.
The U.S. Food and Drug Administration (FDA) has escalated the recall of 30mg Thyroid Tablets, manufactured by Vitruvias Therapeutics, to a Class I designation, the highest-risk category. This move underscores the potential for severe health consequences, including death, associated with the medication.
According to the FDA, the recall, initiated last month, affects one lot of Thyroid Tablets, USP, identified by lot number 504950 and National Drug Code 69680-166-00. The tablets have an expiration date of September 30, 2026, and were distributed nationwide between January 31 and September 30, 2025. Approximately 1,955 of the 3,655 units were sold.
Further testing revealed that the tablets are superpotent, meaning they are stronger than intended. The FDA warns that taking superpotent thyroid medicine can lead to an overactive thyroid, causing symptoms such as weight loss, heat intolerance, fatigue, high blood pressure, chest pain, rapid heartbeat, and heart rhythm problems.
Elderly patients, pregnant women, and infants are particularly at risk, especially with prolonged use. Class I recalls indicate a reasonable probability that exposure to the product could cause serious adverse health effects or death.
Vitruvias Therapeutics, the manufacturer, stated in a recent announcement that it had ceased operations, and its products are now owned or distributed by H2-Pharma LLC. As of the recall notice’s August 24 publication, the company had received no reports of adverse events linked to the lot.
The FDA’s decision to upgrade the recall highlights the severity of the potential health risks associated with the medication. Patients who have purchased or are currently using these tablets are advised to contact their healthcare providers immediately for further guidance and alternative treatment options.
Consumers are urged to check their medicine cabinets for the recalled lot number and National Drug Code. If they find the tablets, they should return them to the pharmacy or healthcare provider for safe disposal.
The recall serves as a reminder of the importance of adhering to FDA guidelines and the potential consequences of non-compliance. Patients and healthcare providers are encouraged to stay informed about recalls and to seek medical advice if they have concerns about their medications.
